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African American Hypertensive Nephropathy Maps to a New Locus
on Chromosome 9q31-q32
Ki Wha Chung,1,* Robert E. Ferrell,3 Demetrius Ellis,1 Michael Barmada,3 Michael Moritz,1
David N. Finegold,1,3 Ronald Jaffe,2 and Abhay Vats1,†
1Departments of Pediatrics and 2Pathology, Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, and 3Department
of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh
Hypertensive nephropathy (HN) and focal segmental glomerulosclerosis (FSGS) are significant causes of end-stage
renal disease (ESRD), but no genes or loci have been associated with this phenotype among African Americans, a
group at high risk. We performed a genomewide linkage scan with ∼400 microsatellite markers on 23 individuals
of a large four-generation African American family with 18 affected individuals (7 with ESRD), in which the 13-
year-old proband (also with ESRD) presented with hypertension and proteinuria (2–4 g/day) and underwent a
kidney biopsy that revealed FSGS-like lesions with arteriolar thickening. A genomewide scan revealed LOD scores
of 12.5 for markers on chromosomes 3 and 9, and fine mapping was performed on 5 additional members (total
28 members) that showed a maximum multipoint LOD score of 5.4 in the 9q31-q32 region, under an autosomal
dominant model with 99% penetrance. This 8-cM (6-Mb) region is flanked by markers D9S172 and D9S105, and
further candidate gene sequencing studies excluded the coding regions of three genes (ACTL7A, ACTL7B, and
CTNNAL1). To our knowledge, this is the first report of a locus, denoted as “HNP1,” for the HN/FSGS phenotype
in a large African American family with dominantly inherited nephropathy characterized by ESRD, hypertension,
and some features of FSGS.
Hypertension is a major public health problem in the
Western world and may result from a variety of renal
disorders (Caetano et al. 2001; Adamczak et al. 2002;
Torpy et al. 2002; Hayden et al. 2003). Although the
number of hypertensive patients in the United States has
doubled since 1980, the frequency of end-stage renal
disease (ESRD) has been increasing geometrically (Cae-
tano et al. 2001). Previous epidemiological studies found
that only a few hypertensive patients develop renal in-
jury; however, more recent clinical observations have
revealed that the relative risk of developing ESRD is
increased by as much as 20-fold in hypertensive patients
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(Klag et al. 1996; Moore et al. 1999; Agodoa et al.
2001). A genetic predisposition to develop both hyper-
tension and hypertensive ESRD is suggested by several
observations. Family studies have shown that hyperten-
sion is more frequent in first-degree relatives of patients
with primary glomerulopathies or diabetic nephropathy
than in the general population (Adamczak et al. 2002).
Also, several studies have shown that African Americans
are more likely than their white counterparts to develop
hypertension-related ESRD (Marcantoni et al. 2002;
Hayden et al. 2003; Kaperonis and Bakris 2003). Hy-
pertension-related ESRD, or hypertensive nephropathy
(HN), is a distinct histologic entity; however, in clinical
practice, a kidney biopsy is not always performed when
an affected individual presents with long-standing hy-
pertension and renal failure. Clinically diagnosed HN
can thus be a heterogeneous entity and may include sev-
eral distinct disorders, including focal segmental glomer-
ulosclerosis (FSGS).
Etiological factors responsible for HN and FSGS are
largely unknown, but there appears to be a strong
genetic risk for both conditions. Recently, several ge-
nomic loci (i.e., 2p24-p25, 15q, 17q21, 12p13, 4p16,
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Figure 1 Pedigree of family CHP 109. Squares indicate males, and circles indicate females. Slashes indicate deceased individuals. Blackened
symbols indicate affected individuals; unblackened symbols indicate unaffected individuals. Symbols that contain small blackened circles indicate
that the individual had hypertension alone (i.e., urinalysis revealed no abnormal results). Asterisk (*) indicates individual whose DNA was used
for genomewide scan. Plus symbol () indicates that alleles for the individual were inferred. “U” indicates that disease status of individual was
unknown.
and 3q21) have been reported to be linked to essential
hypertension, but they are not typically associated with
renal failure or ESRD (Xu et al. 1999a, 1999b; Lifton et
al. 2001; Angius et al. 2002). Indeed, evidence in rodent
models suggests that the predisposition to nephropathy
and hypertension may be under separate genetic control
(Brown et al. 1996; Churchill et al. 1997). Recent mo-
lecular genetic studies of FSGS, a progressive and po-
tentially inherited nephropathy, have identified several
genes on chromosomes 19q13 (i.e., nephrin [MIM
602716], a actinin 4 [MIM 60438]), and 1q25 (podocin
[MIM 604766]), as well as a locus on 11q21 (FSGS2
[MIM 603965]) (Lenkkeri et al. 1999; Winn et al 1999;
Boute et al. 2000; Kaplan et al. 2000; Winn 2002). Hy-
pertension is generally a key feature in these genetic
causes of renal failure, which are characterized by either
significant proteinuria or full-blown nephrotic syndrome.
Although no definitive genomic loci have been described
for HN, a locus for a progressive nephropathy with hy-
pertension was recently reported on 1q21 in a large mul-
tigenerational Israeli family of Iraqi Jewish origin (RFH1
[MIM 161900]) (Cohn et al. 2000). It is quite likely that
several genes are responsible for the phenotypes that re-
semble HN or FSGS.
Here, we describe a large, four-generation African
American family (CHP 109), residing in western Penn-
sylvania (fig. 1), with an autosomal dominant nephrop-
athy. The disorder was clinically diagnosed as HN in
multiple family members, and one member demon-
strated features of FSGS on renal biopsy. We performed
a genomewide linkage scan on 23 members, to identify
the putative genetic locus associated with HN in this
family. To our knowledge, this is the first locus to be
identified for the HN/FSGS phenotype in African Amer-
icans, a group that carries a high risk of HN.
Evaluation of family members included a complete
history, urinalyses, and hematological and biochemical
investigations; in addition, renal histological studies
were performed in the proband. Since the majority of
the family members in this pedigree presented with
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Figure 2 Kidney biopsy findings in CHP family 109. A, PAS stain shows a glomerulus with sclerosing lesions in a number of lobules,
imparting a “nodular” appearance in collapsed segment (arrow). B, PAS-M stain (Jones silver methenamine) shows the range of glomerular
lesions from globally sclerotic to partial glomerular preservation. Interstitial fibrosis is present with entrapped atrophic tubules. C, Immuno-
peroxidase-DAB stain for the presence of IgM reveals mesangial/perimesangial deposition. D, Two views of smooth muscle actin stains showing
prominent and thickened muscular walls of small arteries and arterioles. E, Tissue for electron microscopy consisted of only partly or fully
sclerosed glomeruli. A partially preserved segment of a sclerosing glomerulus is shown with moderately dense deposits (arrows) in basement
membrane in a distribution similar to that of the IgM in panel C.
hypertension in the 4th or 5th decade of life, they were
classified as affected on the basis of the following cri-
teria: (a) if, at any age, they had ESRD requiring dialysis
or renal transplantation or if they had elevated blood
urea nitrogen (BUN) and serum creatinine levels (more
than twice as high as normal for their age); (b) if they
had hematuria (110 red blood cells [RBC] per high-
power field [HPF]) and/or 12 protein in urine, as
shown by qualitative urinalysis, in the absence of other
systemic diseases that are likely to lead to proteinuria
or hematuria; or (c) if, by the age of 40 years, they had
documented hypertension, with or without urinary or
renal functional abnormalities, that required antihyper-
tensive therapy. They were classified as unaffected if they
were 140 years of age and were normotensive and had
no detectable hematuria or proteinuria on qualitative
urinalysis or if they were unrelated married-in spouses.
Disease status was categorized as unknown if no clinical
information was available or if the individual was 40
years of age and had no evidence of high blood pressure
or anomalies of urinary or renal function.
The proband (individual IV-3 [indicated by an arrow
in fig. 1]), a 13-year-old boy, presented to the pediatric
renal clinics at the Children’s Hospital of Pittsburgh, with
hypertension (systemic blood pressure range 150–170/
80–100 mmHg) and mild renal insufficiency (serum cre-
atinine 1.6 mg/dl; BUN 22 mg/dl). Investigations re-
vealed 3–4 nonorthostatic proteinuria and hematuria
(20–40 RBC/HPF), hemoglobin 10 g/dl, white blood cell
count 7,800/mm3, and normal serum complements and
lupus serology. Kidney biopsy showed a range of glom-
erular changes (fig. 2). Of the 17 glomeruli seen, 2 were
morphologically normal, and the rest had focal and seg-
mental sclerosing features or were globally sclerotic. Col-
lapsed lobules in some of the segmentally affected glo-
meruli showed a hyaline appearance that did not extend
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Table 1
LOD Scores of Several Candidate
Regions for HN/FSGS
Location and
Linked Marker
Two-Point
LOD Score
at vp0 Gene
1q21:
D1S534 16. 51 RFH1
D1S1653 4. 98
D1S1679 3. 27
1q25:
D1S1677 . 01 NPHS2
D1S1589 7. 18
D1S518 5. 81
11q21-q22:
D11S1998 14. 45 FSGS2
D11S4464 7. 78
D11S1304 9. 19
19q13:
D19S245 6. 39 ACTN4
D19S559 6. 31 NPHS1
D19S246 6. 73
to afferent arterioles and imparted a slightly nodular-
sclerotic appearance. Amyloid stains in the hyalinized
segments were negative. Residual capillary membranes
in the unaffected segments were of normal thickness.
Mesangial cellularity and matrix were not increased.
There was patchy tubular atrophy and interstitial fibro-
sis without an inflammatory component. Immunostains
revealed moderate deposits of C3 in most glomeruli in
a diffuse but coarsely granular pattern that also extended
to afferent arterioles, and the deposits were graded as
2–4. The muscular walls of the small arteries and
arterioles were prominent, and immunostaining for
smooth muscle actin showed them to be thicker than
arterioles seen in kidney biopsy specimens of other in-
dividuals with nephrotic syndrome or FSGS. Deposits of
IgM were present only in the collapsed segments and in
the mesangium of sclerosing lobules, which correlated
with moderately dense deposits within the basement
membranes seen on electron microscopy (EM). The elec-
tron dense deposits are generally not seen in typical
FSGS. The tissue examined by EM, however, had only
sclerosing and collapsed glomeruli, and the ultrastruc-
tural details of the more preserved glomeruli could not
be evaluated. After the initial presentation, this patient
rapidly progressed to ESRD within 1 year and was nor-
moglycemic throughout the period prior to cadaveric
renal transplantation at 14 years of age. The posttrans-
plant course was also complicated by severe hyperten-
sion, and the patient had an abrupt loss of allograft
function ∼2 years post transplantation.
There were 18 affected individuals in the family, as
defined by the presence of hypertension, renal failure,
and abnormal urinalysis results. Besides the proband,
six additional family members (I-2, II-2, II-5, II-7, II-9,
and II-11) had ESRD that typically developed in the 5th
or 6th decade of life after 20–30 years of hypertension.
Hypertensive renal failure was diagnosed in individual
I-2 when he was in his 50s, 10 years prior to his death
while receiving hemodialysis (HD). II-2 was diagnosed
clinically to have hypertensive nephropathy and first re-
ceived HD in her early 70s, after several decades of being
hypertensive. II-5 was also diagnosed with HN and died
while on HD at 72 years of age. II-11 died in her 80s,
after undergoing dialysis for almost 4 years, with a di-
agnosis of HN. II-7 is currently receiving HD, and II-9
is hypertensive with renal failure. Other affected indi-
viduals in generations III and IV (except GPID IV-2) were
found to be hypertensive prior to age of 40 years and
generally required multiple agents to control blood pres-
sure. No abnormalities were detected in the urine of
these individuals (except IV-4 and IV-5, for whom results
of urinalysis were not available). GPID IV-2 had 2
protein in urine and 1–2 hematuria, and urinalysis
showed white blood cell and mixed cellular casts. In
general, none of the affected individuals (except III-17)
were obese, and, except in the proband, the diagnosis
of HN was made on clinical grounds rather than kidney
biopsy.
The maximum attainable LOD score for this pedigree
was estimated by the SLINK program (Weeks et al.
1990), under the assumption of a four-allele system with
equal frequencies, a 5% recombination with the disease
locus, and a disease allele frequency of 0.0001. A set of
1,000 iterations was generated, and maximum attain-
able LOD score was calculated using the MSIM program
for various v. These studies showed that family CHP
109 was capable of generating a maximum two-point
LOD score of 4.8, under an autosomal dominant model
with a penetrance of 99%. We then obtained genomic
DNA from EDTA-anticoagulated whole blood, by use
of the salting-out procedure, for the genomewide scan
(Miller et al. 1988; Vats et al. 2000). These studies were
performed after obtaining informed consent and were
approved by the human rights committee of the Chil-
dren’s Hospital of Pittsburgh. A genomewide linkage
scan was performed on 23 individuals, and 5 additional
family members (total of 28 individuals) underwent fine
mapping. Fluorescent genotyping was performed by
mammalian genotyping service facilities at Marshfield
Clinics, using ∼400 microsatellite markers of screen-
ing set 10, which provided an average spacing of 9
cM across the genome. The PCR for fine mapping and
candidate gene sequencing was performed by standard
methods, and PCR products were analyzed on an ABI
3700 capillary analyzer (Applied Biosystems) at the Cen-
ter for Human Genetics and Integrative Biology of the
University of Pittsburgh. The genotyping data were an-
alyzed using GENOTYPER software (version 3.7; Ap-
424 Am. J. Hum. Genet. 73:420–429, 2003
Table 2
Two-Point LOD Scores for Analyzed Markers in Chromosome 9q31-q32 Region
MARKER
LOD SCORE AT v p
.00 .05 .10 .15 .20 .25 .30 .35 .40 .45
D9S922 6.09 2.18 1.24 .73 .42 .22 .10 .04 .01 .00
D9S1120 6.41 2.22 1.21 .68 .37 .18 .07 .01 .00 .00
D9S257 8.68 1.00 .28 .04 .19 .22 .19 .12 .04 .01
D9S318 6.16 1.98 .96 .47 .19 .05 .02 .04 .03 .01
D9S197 8.33 1.42 .44 .01 .22 .29 .27 .19 .08 .00
D9S176 6.11 .42 .25 .51 .59 .57 .47 .34 .19 .07
D9S53 1.07 2.45 2.38 2.18 1.91 1.60 1.26 .90 .53 .19
D9S172 2.28 3.54 3.43 3.17 2.83 2.44 2.00 1.52 1.01 .48
D9S1677 2.67 3.91 3.76 3.47 3.10 2.67 2.20 1.68 1.12 .56
D9S105 3.93 3.64 3.32 3.00 2.61 2.28 1.89 1.47 1.02 .53
D9S302 .28 2.64 2.81 2.72 2.50 2.20 1.83 1.41 .95 .47
D9S154 3.03 1.53 2.01 2.10 2.02 1.82 1.54 1.20 .80 .39
D9S934 .20 1.58 1.58 1.46 1.27 1.05 .81 .56 .32 .12
D9S195 4.05 .55 1.07 1.20 1.17 1.04 .85 .62 .37 .14
D9S1825 .12 .07 .03 .01 .01 .02 .02 .02 .02 .01
D9S2157 2.50 .20 .22 .38 .42 .40 .35 .27 .18 .09
D9S1838 1.54 .40 .78 .90 .90 .82 .69 .52 .33 .14
plera) and were entered in a PROGENY2000 database
management system (Progeny Software). The sequencing
reactions for candidate genes were performed using the
BigDye technique, and data were analyzed using Se-
quencher software (Gene Codes).
The genotyping data were assessed by use of the
PedCheck program, to identify and correct Mendelian
errors (O’Connell and Weeks 1998). The linkage was
calculated under a dominant model with a penetrance
of 0.99, without phenocopy, and under the assumption
of a disease allele frequency of 0.0001, using the GENE-
HUNTER and VITESSE statistical programs for each
marker in the genomewide scan (O’Connell and Weeks
1995; Kruglyak et al. 1996). Marker allele frequencies
were estimated from the unrelated spouses in the family.
Two-point and multipoint LOD scores (Z scores), and
Z-1 CIs were calculated for fine mapping data, using the
VITESSE algorithm as described elsewhere (O’Connell
and Weeks 1995). Haplotype analysis was performed by
use of SIMWALK software and also via visual inspection
(Weeks et al. 1995).
Analyses of genotyping data revealed negative LOD
scores for chromosomal regions 1q25, 19q13, and 11q21-
22, which are known to contain loci for familial FSGS
genes, and also for 1q21 markers associated with the
RFH1 locus (table 1). Analysis of genomewide data by
GENEHUNTER identified two chromosomal regions
with LOD scores 12. These regions, chromosomes 9q31-
32 and 3p24-pter, were further investigated by fine map-
ping, using markers spaced 1–5 cM apart and using the
following fluorescent dye–labeled markers obtained
from Research Genetics/Invitrogen: D9S257, D9S318,
D9S197, D9S176, D9S53, D9S172, D9S1677, D9S105,
D9S302, D9S154, D9S934, D9S195, D9S1825, and
D9S2157 for chromosome 9q31-32; and D3S1307,
D3S1297, D3S3050, D3S1304, and D3S1286 for chro-
mosome 3p24-pter. A peak two-point LOD score of 3.93
for marker D9S105 was obtained through VITESSE
analysis, with 99% penetrance and a disease allele fre-
quency of 0.0001 at (table 2). A Z score of 5.42vp 0
was obtained for the trait locus, denoted “HNP1,” in
the 9q32 region between markers D9S1677 and
D9S105. These LOD score calculations were robust to
changes in presumed marker allele and disease allele fre-
quencies. Similar results were generated when compu-
tation of LOD scores was performed with disease allele
frequencies of 0.1–0.00001, as well as when marker al-
leles were assumed to be equally frequent. Figure 3
shows the multipoint LOD score and nonparametric
linkage (NPL) score plots as well as an ideogram of the
linked region. Linkage to chromosome 3 was excluded
upon fine mapping (LOD scores ranging from 1.2 to
10.0 for the all the analyzed markers). By using the
“maximum LOD 1” method, we constructed a sup-
port interval with an asymptotic CI 195% (Winn et al.
1999). The HNP1 support interval was flanked by
marker D91677 proximally and by D9S302 distally. The
haplotypes for nine markers—in the order cen-D9S197,
D9S176, D9S53, D9S172, D9S1677, D9S105, D9S302,
D9S154, D9S934-tel—are shown below each individual
genotyped (fig. 1). Recombinant events in individuals
III-10, III-11, III-13, and IV-2 also localize the linked
region to an ∼8-cM (6-Mb) interval bounded by markers
D9S172 and D9S105.
An analysis of the region of interest on chromosome
9q31-32 showed several strong candidate genes, in-
cluding Kruppel-like factor 4 (KLF4 [MIM 602253]),
actin-like 7A (ACTL7A [MIM 604303]), actin-like
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Table 3
Mutation Screen for Candidate Genes in 9q31-q32
Gene and Region
PCR
Product
(bp) Forward and Reverse Primers Variations
ACTL7A:
Promoter 527 3′-TGAGGCCTACCATGAGCTGCTTGC-5′ SNP at 739 from start codon (A/G)
5′-ATCCCTTATTCTAGTCGGTGGCGG-3′
5′ UTR, N-term 512 3′-CCACCCTGCTTTTGCTCTTAACG-5′
5′-GGCCATCCCTTAAAGAGGCAGTC-3′
Coding 498 3′-ACCAAGAAGGTGGGCAACCAG-5′ Missense mutation (Ala481Pro)
5′-GTTGGTGTGTGGGCTCAGTGG-3′
Coding 540 3′-TCCGACAAGAGATGAAGATCGCC-5′
5′-CCAGCTGCATGGACTTGATGAGA-3′
Coding 527 3′-TGGGAAGGAGATTCAGCTGTGCC-5′ Missense mutation (Val1018Met)
5′-CACACTGTGGAGGGGCATATGAG-3′
C terminal, 3′ UTR 446 3′-GTACGAGGAACACGGGCCTTTCT-5′
5′-TGCCCCAACAGCATTTACCCTCT-3′
ACTL7B:
Promoter 480 3′-GCA TCACCTCTCTAGAGCACC-5′
5′-GCATTTCCATGCCTAAGGTGTTCA-3′
5′ UTR, N terminal 496 3′-TGCCTTACTGGAGGGGCTCAAAT-5′
5′-GGGCTTCATCTTGAGCTGAGTGG-3′
Coding 498 3′-GAGGCAGATGGCGACAAGGAACA-5′
5′-GCGTACTTCTCCCGGTTGCTGCT-3′
Coding 496 3′-TGGGAGTACATCTTCCGCACCGCC-5′
5′-GCTCCTGGCCAATAGTGATGAGTT-3′
Coding 524 3′-GGACGACCACCTGCACATCATAG-5′
5′-ATGCCGAGGCTCAGCACTTGCTG-3′
C terminal, 3′ UTR 511 3′-CAGCTCTGGGTCAGCAAGGAAGA-5′
5′-GAAACAGGAGACTGGAGTCGGAC-3′
CTNNAL1 Exon:
1 477 3′-AGAAGAGATAAGGGCGGGGCCAT-5′
5′-GGCGGGAAGGAGAAGAGGGGC-3′
2 429 3′-TGCCAGGCTTCATTTTCTTTGAC-5′
5′-GTATTCGCGGAAGCTAATCCAGG-3′
3 380 3′-GCTGAGTTTCTCCTCATTGTGCC-5′
5′-ACAAGCCAAGCAATCCACCACTA-3′
4 354 3′-CCCCTTGTGTGTCTTCTATCTGGC-5′ SNP at intron 3 (84 from exon 4): C/G
5′-CCAGTCCAAACAATCCTAACGATC-3′
5 367 3′-TCACATGGTCTTAGACTCCTCCGT-5′
5′-ACACCATGTTCTGCTGAGCTGTTC-3′
6 421 3′-GTGAGCCAGGGACCCAGGAGATT-5′
5′-GAGCCGAGATCACACCACTGCAC-3′
7 442 3′-TCCCCTCAGCTTGGGAAAAGGAA-5′
5′-CCTGTCCCATTCTGGAACAAATTC-3′
8 289 3′-GAGATGCGGTAACATTACATGTAT-5′
5′-GAATTACGGGCATGAGCCACCAT-3′
9 494 3′-AGTGGAACCCATGGAACTGCTTT-5′ CA repeats at intron 8 (8 from exon 9): (CA)5/(CA)4
5′-TTTAGAGGCCAGACTGTTGCAGG-3′
10 500 3′-CACCTTGCCATGATTGGATAGGA-5′ SNP at intron 10 (94 from exon 10): C/T
5′-GCCATGTTCTGGCACACTACCAA-3′
11 388 3′-ATTGCCCAACATGGAGCTTGTGT-5′
5′-TCATTTGCAGTTGAGGTTTGGCA-3′
12 363 3′-GGAGAGGTGGAGATTGACCAGCA-5′
5′-TTGTGGTAGAGGGGAGCAGCAAC-3′
13, 14 609 3′-GGCACTGACTTGCTTTCTCTGGC-5′ Deletion (G/D) at intron 12 (139)
5′-ACCGACTTTAACCTGTCAATGATT-3′ SNP (T/G) at intron 12 (122)
15 554 3′-TTCAGTGATATGCCTCATCAAGGTA-5′
5′-CCCACTTTTAGCCCGAAATTAAA-3′
16, 17 476 3′-ACCAACTATCCATAGACATCAGTC-5′
5′-AGGAAATAAATTGCCCTTCTGTGG-3′
18, 19 610 3′-AATGGTAAGGTCTTTTAAGTACTA-5′
5′-GACAGTTGGGATATTTGGTTTGA-3′
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7B (ACTL7B [MIM 604304]), and catenin a–like 1
(CTNNAL1 [MIM 604785]) (fig. 3). KLF4 is a transcrip-
tion factor, whose mRNA is expressed, at a high level, in
the metanephric kidney during early embryonic devel-
opment (Garrett-Sinha et al. 1996). ACTL7A and
ACTL7B are intronless genes situated next to each other,
which encode for actin-like proteins (Chadwick et al.
1999). CTNNAL1 encodes a cadherin-associated pro-
tein that is involved in cell-cell interactions (Zhang et
al. 1998). We have thus far sequenced ACTL7A,
ACTL7B, and CTNNAL1 genes, using the primers
shown in table 3. The results of gene sequencing exper-
iments showed several polymorphisms that did not seg-
regate with affected status (also shown in table 3).
Our results provide strong evidence, in a large African
American family, of an HN susceptibility locus (HNP1)
mapping to chromosome 9q31-q32 that was identified
on a genomewide scan and confirmed by fine mapping.
We ruled out loci on 1q21, 1q25, 11p21, and 19q13
regions, which have been previously linked with familial
FSGS or RFH1, because they were consistently associ-
ated with negative or low LOD scores (Cohn et al. 2000;
Winn et al 2002). An examination of the UCSC genome
browser showed 33 genes, of which 15 are known and
the rest are computer predicted, in the 6-Mb HNP1 locus
flanked by D9S172 and D9S105. We further analyzed
several candidate genes from this region. ACTL7A and
ACTL7B appeared to be strong candidates, in view of
the involvement of ACTN4, located on 19q13, with fa-
milial FSGS (Kaplan et al. 2000). CTNNAL1, an ad-
hesion molecule, was also studied, because several re-
lated molecules, including catenin, are involved in the
maintenance of podocyte architecture. However, we
have excluded the coding regions of these genes as being
responsible for this phenotype. Studies, including se-
quencing of KLF4 gene, are ongoing to narrow the in-
terval and to identify the responsible gene.
Previous linkage studies have suggested significant
genetic heterogeneity for FSGS and HN phenotypes.
We had reported linkage between chromosome 19q13
and an autosomal dominant FSGS with late-onset hy-
pertension in another large African American family
(CHP 101) that also resides in western Pennsylvania
(Vats et al. 2000). Genomic DNA sequencing excluded
the two main candidate genes (NPHS1 and ACTN4) and
several other genes (authors’ unpublished data). We also
recently found a linkage between 11q24 and a nephro-
pathy characterized by hypertension, thin basement
membranes, and deafness in an Asian Indian family
(CHP 177) (Prakash et al. 2003). Although several genes
for the FSGS phenotype have been identified, they are
mostly associated with the disease in white populations.
In contrast to the FSGS loci, the locus described by Cohn
et al. (2000) is the closest description of another possible
HN locus, but it is reported in a different ethnic group.
Cohn et al. ascertained a large Israeli family of Iraqi Jew-
ish origin with an autosomal dominant form of adult-
onset nephropathy. Hypertension was the main presenting
sign in all patients and was associated with progressive
renal failure. The report of Cohn et al. (2000), however,
did not describe any specific histological entity. One in-
dividual with a creatinine level similar to that of our
proband, had 3 sclerotic and 7 normal glomeruli (of the
10 examined), along with interstitial fibrosis and mild
tubular atrophy. Another hypertensive individual in that
report had a serum creatinine level of 1.7 mg/dl and
showed mild thinning of the glomerular basement mem-
branes on electron microscopy, but no other significant
alterations were revealed by microscopy or immuno-
staining. By performing a genomewide linkage search,
Cohn et al. localized the disease locus to an 11.6-cM
region on 1q21, which is flanked by markers D1S2696
and D1S2635 (maximum LOD score 4.71, with D1S305
at ). They considered atrial natriuretic peptide re-vp 0
ceptor-1 (NPR1 [MIM 108969]), which maps to 1q21,
as a candidate disease gene, since a polymorphic allele
of this gene is associated with essential hypertension
(Nakayama et al. 2000); however, they concluded that
the disorder was distinct from a form of medullary
cystic kidney disease (MCKD1 [MIM 174000]) that
also maps to 1q21. These findings, along with those of
the family described here, underscore the genetic het-
erogeneity of the HN/FSGS phenotype.
Although HN and FSGS are two distinct disorders and
HN is typically associated with histologic lesions char-
acterized by ischemic changes and an absence of im-
munofluorescence findings, HN is usually diagnosed, in
clinical practice, without renal biopsy or any evidence
that hypertension actually preceded the renal disorder
(Torpy et al. 2002; Kaperonis and Bakris 2003). Thus,
HN can clinically resemble many other nephropathies
including FSGS (Freedman et al. 1995; Preston et al.
1996; Bohle et al. 1998; Martinez-Maldonado 1998;
Ruilope and Segura 2002). In contrast to HN, FSGS is
characterized by segmental glomerular scars involving
some (focal) glomeruli (Habib 1973), and, although se-
vere proteinuria is a hallmark of FSGS, low grades of
proteinuria are not uncommon in HN. Recent studies
show a trend toward an increase in the incidence of FSGS
and HN, which is especially evident in African Ameri-
cans. The reason for this trend is unclear, but genetic
factors have been implicated (Haas et al. 1997; Mar-
cantoni et al. 2002; Tucker 2002). Also, FSGS is fre-
quently associated with hypertension and tends to pro-
gress to ESRD (Schwartz et al. 1995). The overlapping
nature of the HN and FSGS phenotypes was also evident
in the current study, in which several members presented
with nonsyndromic HN and progressed to ESRD. Many
of the members were clinically diagnosed with HN,
whereas the index case was found to have features of
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FSGS. Indeed, in one study, “true” HN was seen in only
48% of 56 white patients in whom HN was clinically
diagnosed (Zucchelli and Zuccala 1996), and another
study showed that 19% of a cohort of patients with clin-
ical HN actually had FSGS lesions (Caetano et al. 2001).
In summary, we report linkage of HN to a locus on
chromosome 9q31-q32 in a large African American fam-
ily with dominantly inherited ESRD and hypertension
and with features of FSGS. With the identification of the
first such locus, further studies can be performed to iden-
tify the causative genes and to evaluate the importance
of this locus in other African American families with this
phenotype. The detection of HN genes involved in this
high-risk population will allow dissection of molecular
mechanisms involved in this important public health
problem.
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